What Dato-DXd is
Datopotamab deruxtecan (“Dato-DXd”) is an antibody–drug conjugate (ADC). It uses an antibody that locks onto the TROP-2 protein on many lung-cancer cells and then delivers a potent chemotherapy payload directly inside the tumor. Think of it as a guided “smart bomb” designed to spare more of your healthy tissue.
Where regulatory approval stands today
On June 23, the FDA has granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway; Dato-DXd) for adults with locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) who have already been treated with systemic therapies, including EGFR-targeted treatments.
What to Expect from Dato-DXd in Lung Cancer
This document summarizes key clinical trial findings for Dato-DXd in non-small cell lung cancer (NSCLC), focusing on results from two studies: the Phase II TROPION-Lung05 and the Phase III TROPION-Lung01 trials. Special attention is given to the outcomes in patients with EGFR-mutated, including a deeper analysis of Dato-DXd’s potential role in this molecular subgroup.
Download the following document for FREE HERE
Pingback: Early Access Program For Non-Approved Medicines Outside the US
Pingback: Cancer News: Updated in June 2025